Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
40
IMRX Quote, Financials, Valuation and Earnings
Last price:
$6.72
Seasonality move
:
-21.18%
Day range:
$6.49 - $6.77
52-week range:
$1.10 - $10.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
323.21x
P/B ratio:
1.89x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
185.84%
Market cap:
$430M
Revenue:
--
EPS (TTM):
-$1.78
Analysts' Opinion
-
Consensus RatingImmuneering Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.83, Immuneering Corp. has an estimated upside of 152.75% from its current price of $6.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $6.66.
Fair Value
-
According to the consensus of 4 analysts, Immuneering Corp. has 152.75% upside to fair value with a price target of $16.83 per share.
IMRX vs. S&P 500
-
Over the past 5 trading days, Immuneering Corp. has overperformed the S&P 500 by 18.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Immuneering Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Immuneering Corp. revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Immuneering Corp. reported revenues of --.
Earnings Growth
-
Immuneering Corp. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Immuneering Corp. reported earnings per share of -$0.38.
Enterprise value:
206.4M
EV / Invested capital:
0.89x
Price / LTM sales:
323.21x
EV / EBIT:
--
EV / Revenue:
255.84x
PEG ratio (5yr expected):
-0.34x
EV / Free cash flow:
-4.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$528.4K
Return On Assets:
-68.97%
Net Income Margin (TTM):
--
Return On Equity:
-78.54%
Return On Invested Capital:
-74.71%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $500 | -- | -- | -- | -- | |
| Gross Profit | -$767.7K | -$724K | -$528.4K | -$175.6K | -$86.2K | |
| Operating Income | -$56.1M | -$61.8M | -$64.2M | -$15.3M | -$15.4M | |
| EBITDA | -$55.3M | -$61.1M | -$63.7M | -$15.1M | -$15.3M | |
| Diluted EPS | -$1.87 | -$1.97 | -$1.78 | -$0.49 | -$0.38 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $153.3M | $120M | $100.6M | $55.3M | $229.1M | |
| Total Assets | $164M | $133.7M | $113.9M | $68.6M | $241.1M | |
| Current Liabilities | $5.3M | $7.3M | $5.6M | $6.9M | $9.5M | |
| Total Liabilities | $5.7M | $11.8M | $9.9M | $10.8M | $13.1M | |
| Total Equity | $158.3M | $121.9M | $104M | $57.7M | $228M | |
| Total Debt | $482K | $4.5M | $4.2M | $3.9M | $3.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.9M | -$52.3M | -$50M | -$13.5M | -$12M | |
| Cash From Investing | $12.3M | $24.1M | $5.5M | -$5.4M | -$7.3K | |
| Cash From Financing | $28.2M | $5.4M | $226.9M | $4.4M | $213.2M | |
| Free Cash Flow | -$49.2M | -$52.5M | -$50M | -$13.5M | -$12M | |
IMRX
Sector
Market Cap
$430M
$27.9M
Price % of 52-Week High
66.07%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-51.04%
-1.55%
1-Year Price Total Return
185.84%
-17.49%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.17
200-day SMA
Buy
Level
$4.28
Bollinger Bands (100)
Buy
Level
4.94 - 7.62
Chaikin Money Flow
Sell
Level
-277.4M
20-day SMA
Buy
Level
$6.28
Relative Strength Index (RSI14)
Buy
Level
55.07
ADX Line
Buy
Level
16.73
Williams %R
Neutral
Level
-20.3947
50-day SMA
Buy
Level
$6.47
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
268.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.6194)
Sell
CA Score
(Annual)
Level (-2.5799)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (10.8284)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, IMRX has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IMRX average analyst price target in the past 3 months is $16.83.
-
Where Will Immuneering Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Immuneering Corp. share price will rise to $16.83 per share over the next 12 months.
-
What Do Analysts Say About Immuneering Corp.?
Analysts are divided on their view about Immuneering Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Immuneering Corp. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Immuneering Corp.'s Price Target?
The price target for Immuneering Corp. over the next 1-year time period is forecast to be $16.83 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IMRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Immuneering Corp. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IMRX?
You can purchase shares of Immuneering Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Immuneering Corp. shares.
-
What Is The Immuneering Corp. Share Price Today?
Immuneering Corp. was last trading at $6.72 per share. This represents the most recent stock quote for Immuneering Corp.. Yesterday, Immuneering Corp. closed at $6.66 per share.
-
How To Buy Immuneering Corp. Stock Online?
In order to purchase Immuneering Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IMRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IMRX
Sector
P/E ratio
--
23.75x
PEG ratio
-0.34x
-0.01x
P/B ratio
1.89x
1.81x
Price / LTM sales
323.21x
1.59x
Growth Metrics
IMRX
Sector
Revenue growth
--
4.6%
Earnings growth
22.9%
10.88%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$0.39
-$0.21
Profitability
IMRX
Sector
Profitability FY 2024
-$713.5K
$3.6M
Return on invested capital
-74.71%
-31.84%
Return on assets
-68.97%
-27.96%
Return on equity
-78.54%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
11
Balance Sheet
IMRX
Sector
Total cash
$227.6M
$26.3M
Short term investments
--
$25.7M
Total assets
$52.7M
$76.9M
Long term debt
$3.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
